资讯库
更紧凑的生命科学资讯库。
先搜索，再按来源或主题继续收窄。
针对代谢弱点：缬氨霉素增强生物能量抑制剂对抗耐药与休眠结核分枝杆菌的效力
Tuberculosis (TB) treatment is hampered by monotherapy limitations and phenotypic drug tolerance, citing the need for effective drug combinations. The mycobacterial ele...
Contineum与强生合作的多发性硬化症药物在二期试验中未能改善视力
Contineum Therapeutics’ M1 receptor antagonist has failed to move the needle in a phase 2 vision test for patients with a common form of multiple sclerosis.
强生公司50亿美元阿尔茨海默病希望破灭，抗tau抗体posdinemab二期试验失败
Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. A scheduled data review found the anti-tau antibo...